Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 3/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.30 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989726 | 0.92 | GRIK1 (0.34) | CPB2MMESLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4985864 | 0.90 | KDM4E (0.33) | CPB2SLC1A3SLC1A2SLC1A1AKR1C3 | |
| SCHEMBL4987473 | 0.90 | CPB2 (0.32) | CPB2MMESLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4986226 | 0.87 | CPB2 (0.31) | CPB2AKR1C3AKR1C2 | |
| SCHEMBL4990647 | 0.86 | CPB2 (0.35) | CPB2MMESLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4988099 | 0.86 | SLC1A2 (0.34) | CPB2SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL4993209 | 0.86 | RIPK1 (0.35) | CPB2MMESLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4993312 | 0.85 | MME (0.32) | MMEGRIK1GRIK2 | |
| SCHEMBL4990714 | 0.84 | TAAR1 (0.33) | CPB2SLC1A3SLC1A2SLC1A1AKR1C3 | |
| SCHEMBL4987835 | 0.82 | GRIK1 (0.32) | CPB2MMESLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | CPB2 1747/4885MME 2393/4885SLC1A3 118/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | CPB2 1342/4885MME 2286/4885SLC1A3 128/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | CPB2 1460/4885MME 2084/4885SLC1A3 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.